What Is Harvard Bioscience, Inc. (HBIO) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Harvard Bioscience, Inc. is potentially undervalued at its current price of $6.03. Based on our 13-model framework, Harvard Bioscience, Inc.'s intrinsic value is estimated at a composite fair value of $14.81 — representing +145.7% implied upside — with 6 out of 8 active models confirming this thesis. Model dispersion is worth noting: First Chicago targets $27.22 (+351.4%), versus Dynamic NAV at $0.92 (-84.8%). This +436.1% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About HBIO?
8 of 13 models are currently active for HBIO. Of these, 7 models suggest upside while 1 model suggests overvaluation. The Bayesian DCF estimates HBIO's intrinsic value at $6.20, implying +2.9% upside from the current price. See which stocks rank higher →
How Does HBIO Rank in Laboratory Analytical Instruments?
Among 19 Laboratory Analytical Instruments stocks, HBIO ranks #16 by Quality of Company score. CirclFi's QOC score of 5.2/10 evaluates 32 fundamental signals. A score of 5.2 reflects mixed fundamentals.
Harvard Bioscience, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is HBIO a Value Trap?
CirclFi's Value Trap algorithm assigns HBIO a score of 31/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
8 of 13 models are active for Harvard Bioscience, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Harvard Bioscience, Inc. earns a quality score of 5.2/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +436.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every HBIO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across HBIO's 8 active models, average confidence is 34%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad